Are ADHD and Autism Comorbid? Shared Biology, Overlap Rates, and What to Do

Yes, ADHD and autism are comorbid, and frequently so. Large population studies and meta-analyses put the co-occurrence rate at roughly 20 to 50 percent depending on which direction you count from: about 30 to 40 percent of autistic children meet criteria for ADHD, and about 15 to 25 percent of children with ADHD meet criteria for autism. The two conditions share genetic architecture, overlap in dopamine and GABA signaling, and both affect executive function—yet they are separate diagnoses with distinct trajectories. This article breaks down the mechanisms, the numbers, the diagnostic timeline, and the practical steps for families and clinicians.

The mechanism: why two diagnoses travel together

The short answer is shared biology, not coincidence. Twin and family studies estimate that the genetic correlation between ADHD and autism is roughly 0.3 to 0.4—meaning about a third of the genetic liability is common to both. Genome-wide association studies have identified overlapping risk loci in genes involved in synaptic pruning, neuronal migration, and neurotransmitter transport.

In plain terms: the same genetic risk factors can produce different symptom profiles depending on which brain circuits they most affect.

At the circuit level, both conditions involve atypical function in the prefrontal cortex and the striatum. The prefrontal cortex governs planning, inhibition, and working memory. The striatum gates reward and motor output. ADHD leans toward dopamine transporter dysfunction and reduced reward signaling. Autism leans toward altered GABA signaling, atypical connectivity between brain regions, and differences in the salience network—the system that flags which stimuli matter.

Where the two overlap is executive function. Approximately 50 to 70 percent of autistic people show some degree of executive dysfunction, and nearly all people with ADHD do. This shared bottleneck explains why the behavioral surface can look similar even when the underlying pathophysiology differs.

One non-obvious detail: the diagnostic manual itself created artificial separation for decades. Before the DSM-5 (2013), clinicians were instructed not to diagnose ADHD alongside autism. That single rule suppressed comorbidity recognition for nearly 20 years. When the rule was lifted, prevalence estimates jumped—not because biology changed, but because the diagnostic gate opened.

How common is the overlap? The numbers

The comorbidity rate depends heavily on which population you sample and which direction you measure. Here is a comparison of the major estimates:

The important reconciliation: the 30–40 percent figure applies to autistic populations seeking clinical care, not the general population. In the general population, only about 2 to 5 percent of children carry both diagnoses. The higher numbers reflect referral bias and the fact that clinical samples are enriched for more severe presentations.

A 2019 meta-analysis in the Journal of the American Academy of Child and Adolescent Psychiatry (Rong et al., 2019) pooled 63 studies and found a pooled ADHD prevalence of 28 percent among autistic individuals. That number is the most-cited single estimate and sits comfortably within the 20 to 50 percent range.

Symptom overlap and the diagnostic puzzle

The core challenge is that several symptoms look identical on the surface but arise from different mechanisms. A child who cannot sit still might be hyperactive (ADHD) or might be stimming to regulate sensory input (autism). A child who does not respond to their name might be inattentive (ADHD) or might have a social communication difference (autism).

Here is where the two diverge in ways that matter for diagnosis:

• Social motivation: Autistic children often show reduced social motivation from infancy; ADHD children are typically socially motivated but impulsive.
• Attention profile: ADHD inattention is global and inconsistent; autistic attention is often intensely focused on specific interests (hyperfocus).
• Sensory response: Autism involves atypical sensory reactivity in 80 to 90 percent of cases; ADHD sensory differences are less pronounced and more tied to stimulation-seeking.
• Repetitive behavior: Autism features restricted, repetitive patterns; ADHD features fidgeting and restlessness rather than true repetition.
• Onset: Autism symptoms appear in the first 12 to 18 months; ADHD is typically identified between ages 4 and 7.
• Response to stimulants: Both groups may respond, but autistic children are more sensitive to side effects and often need lower doses.

The practical consequence: when both conditions are present, the clinician must establish that the symptoms are not better explained by the other condition. This is called differential diagnosis, and it is the single hardest task in this field.

The developmental timeline: when each condition appears

The two conditions do not emerge on the same schedule. Recognizing that timeline helps parents and clinicians avoid missing one diagnosis while treating the other.

The key insight from this timeline is that autism is usually identifiable first, often by age 2 or 3. ADHD is usually identified later, around age 6 or 7, when school demands expose the executive function gap. A child diagnosed with autism at age 2 who develops clear hyperactivity at age 6 should be re-evaluated for ADHD—not assumed to be "just autism."

Misconceptions and edge cases

Several myths persist and cause real harm.

Myth one: "You can't have both." This was official policy before 2013 and remains a belief among some older clinicians. The evidence is unambiguous—comorbidity is common.

Myth two: "ADHD medication doesn't work in autism." Stimulants do work in autistic children with ADHD, but response rates are lower (about 50 to 60 percent versus 70 to 80 percent in ADHD alone) and side effects are more frequent. Lower starting doses and slower titration are standard.

Myth three: "Autism explains the inattention." Sometimes it does—but not always. If inattention persists independently of sensory overload and social demand, ADHD should be evaluated separately.

An edge case worth flagging: girls and women are systematically underdiagnosed with both conditions. Autistic girls mask more effectively, and ADHD in girls often presents as inattentive rather than hyperactive. The result is a diagnostic delay of 3 to 5 years on average compared with boys.

Another edge case: intellectual disability. When IQ is below 70, diagnosing ADHD becomes harder because standardized rating scales lose sensitivity. Clinicians must rely more on direct observation and caregiver report.

What to actually do: practical steps

If you suspect both conditions in yourself or a child, the following actions are concrete and evidence-based.

• Request a combined evaluation. Ask for an assessment that screens for both autism and ADHD in the same visit. Separate evaluations often miss the second condition.
• Use validated screeners first. The SNAP-IV or Vanderbilt scale for ADHD and the M-CHAT-R or Social Responsiveness Scale for autism are reasonable starting points. Screeners are not diagnoses, but they guide referral.
• Bring a developmental history. Onset timing, early milestones, and school reports are the strongest diagnostic evidence. A single-office visit cannot replace a longitudinal history.
• Prioritize functional impairment. Treat the condition causing the most impairment first. If hyperactivity is blocking classroom learning, address ADHD before fine-tuning autism supports.
• Coordinate care across providers. Pediatricians, psychologists, speech therapists, and educators should share findings. Fragmented care is the leading cause of missed comorbidity.
• Reassess every 12 to 24 months. Symptom profiles shift with developmental stage. A diagnosis made at age 6 should be revisited at age 10 and again at age 14.

Limitations and what remains uncertain

The science here is strong but not complete. The genetic correlation of 0.3 to 0.4 is well-replicated, but the specific shared variants explain only a fraction of the overlap. Environmental contributors—prenatal factors, early adversity—are hypothesized but not quantified with precision.

Diagnostic instruments remain imperfect. Most ADHD rating scales were validated in non-autistic populations, and most autism instruments do not account for ADHD-driven restlessness. This means comorbidity is probably still undercounted, especially in adults.

Finally, treatment evidence is thinner than diagnosis evidence. There are no large randomized trials of combined pharmacological and behavioral treatment specifically for the comorbid population. Most clinical guidance extrapolates from single-condition trials. That gap is the most important unresolved question in the field—and the reason ongoing reassessment, not a one-time label, remains the standard of care.